Yahoo Finance • 26 days ago
Looking for insights into the US markets one hour before the close of the markets on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. [topmovers] TOP GAINERS TICKER CHANGE... Full story
Yahoo Finance • 26 days ago
Curious to know what's happening on the US markets in the middle of the day on Thursday? Join us as we explore the top gainers and losers in today's session. [topmovers] TOP GAINERS TICKER CHANGE COMMENT SOGP [https://www.cha... Full story
Yahoo Finance • 26 days ago
In today's session, there are notable price gaps in the US markets on Thursday. Take a closer look at the stocks that are gap up and gap down. [gap] GAP UP STOCKS TICKER CHANGE COMMENT SOGP [https://www.chartmill.com/stock/qu... Full story
Yahoo Finance • 26 days ago
As the US market prepares to open on Thursday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses. [premarket] TODAY'S PRE-MARKET GAINERS TICKER CHANGE COM... Full story
Yahoo Finance • 27 days ago
* CEL-SCI Corporation (NYSE:CVM [https://seekingalpha.com/symbol/CVM]) on Wednesday announced [https://seekingalpha.com/pr/20214061-cel-sci-announces-pricing-of-10-million-public-offering] the pricing of a public offering of 1,111,200 sh... Full story
Yahoo Finance • 2 months ago
* CEL-SCI (NYSE:CVM [https://seekingalpha.com/symbol/CVM]) announced on Friday the pricing of a best-efforts offering of 1,500,000 shares of its common stock. * Each share of common stock is being sold at an offering price of $3.82 per... Full story
Yahoo Finance • 2 months ago
VIENNA, Va. - CEL-SCI Corporation (NYSE American:CVM), a clinical stage cancer immunotherapy company with a market capitalization of $26 million, announced Friday it has priced a best-efforts offering of 1.5 million shares of its common st... Full story
Yahoo Finance • 2 months ago
Investing.com -- CEL-SCI Corporation (NYSE American:CVM) stock surged 25% after announcing a partnership with a leading Saudi pharmaceutical company for its cancer immunotherapy Multikine. The agreement covers regulatory and commercial ac... Full story
Yahoo Finance • 2 months ago
VIENNA - CEL-SCI Corporation (NYSE American:CVM) has reached an agreement with a leading Saudi Arabian pharmaceutical company to pursue regulatory approval and commercialization of its cancer immunotherapy Multikine in Saudi Arabia, accord... Full story
Yahoo Finance • 2 years ago
VIENNA, Va., November 16, 2023--(BUSINESS WIRE)--CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced the pricing of an offering of 2,490,000 shares of its common st... Full story
Yahoo Finance • 2 years ago
VIENNA, Va., April 28, 2023--(BUSINESS WIRE)--CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE American: CVM), a Phase 3 cancer immunotherapy company, today announced the pricing of its underwritten confidentially marketed public off... Full story
Yahoo Finance • 3 years ago
Pioneer in the field of regenerative medicine who brought four products from concept through FDA approval and market launch VIENNA, Va., August 08, 2022--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) today announced the appoin... Full story